NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
Karyopharm investors fasten their seatbelts
A binary Xpovio catalyst is set for March.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
AstraZeneca goes early with Gracell
AZD0120’s first pivotal trial will test settings as early as the second line.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
OnKure is no longer the only game in town
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
